Mirvetuximab soravtansine Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Mirvetuximab soravtansine Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
29
Registered trials
61
Result records
3
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Mirvetuximab soravtansine can convert its Antibody drug conjugate (ADC) profile and FOLR1 x Tubulin biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Mirvetuximab soravtansine (query alias: Mirvetuximab soravtansine) |
|---|---|
| Modality / target | Antibody drug conjugate (ADC); FOLR1 x Tubulin; FOLR1 antagonists, Tubulin inhibitors |
| Highest global status | Approved |
| Originator | ImmunoGen, Inc. |
| Active developers | AbbVie, Inc., Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd., ImmunoGen, Inc. |
The MCP disease footprint includes Platinum-sensitive epithelial ovarian cancer, Fallopian Tube Carcinoma, Ovarian Cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07059845 | Phase 2 | Recruiting | 400 | Substudy 1, 2, and 3: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) (any grade, Grade >= 3) |
| NCT06890338 | Phase 2 | Recruiting | 140 | Objective Response (OR) by Independent Central Review (ICR) |
| NCT06682988 | Phase 2 | Recruiting | 110 | Randomized Phase 2 Cohort: Percentage of Participants with Grade >= 2 Treatment-Emergent Corneal Adverse Events (AEs) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Phase 1/2 Open-label Study to Evaluate The Safety, Tolerability, Efficacy And Pharmacokinetics of Mirvetuximab Soravtansine (TAK-853) in Japanese Patients With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors
Phase 1/2; n=28; evaluation: not stated. Reported fields: -; -; -
A randomized phase II trial of mirvetuximab soravtansine in folate receptor alpha (FRα)–high recurrent ovarian cancer eligible for platinum-based chemotherapy (MIROVA/AGO-OVAR 2.34).
Phase 2; n=145; evaluation: Negative. Reported fields: mPFS = 9.53 month ; mPFS = 9.79 month
Real‑world overall survival with mirvetuximab soravtansine compared with chemotherapy after multiple lines of platinum therapy in gynecologic cancers.
Not Applicable; n=1030; evaluation: Positive. Reported fields: OS(1-year) = 82.0 % ; OS(1-year) = 88.0 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Mirvetuximab soravtansine addresses Platinum-sensitive epithelial ovarian cancer, Fallopian Tube Carcinoma, Ovarian Cancer. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Antibody drug conjugate (ADC)—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2023-11-30 | AbbVie wraps up its $10.1B buyout of ImmunoGen well ahead of schedule | Approved | US$10,100.0M stated total |
| 2023-08-28 | ImmunoGen Announces Collaboration with Takeda to Develop and Commercialize ELAHERE® in Japan | Approved | US$34.0M upfront |
| 2020-10-19 | Huadong partners with ImmunoGen to develop and commercialize mirvetuximab soravtansine for cancer treatment in Mainland China, Hong Kong, Macau, and Taiwan. | Phase 3 | US$40.0M upfront; US$265.0M milestones; US$305.0M stated total |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- CLDN18.2 assay, cutoff, and intratumoral heterogeneity
- Payload-related toxicity and dose intensity
- Crowding from antibodies, bispecifics, CAR-Ts, and competing ADCs
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
